iTONE Trial (exercIse Training in pulmONary hypertEnsion) Exercise Program for Pediatric PH

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age8-18
SponsorChildren's Hospital of Philadelphia

About this trial

Children with pulmonary hypertension (PH) engage in less physical activity than their peers. This is a concern since adult data support exercise as a non-pharmacologic treatment for PH. Despite adult data, therapeutic exercise has not been widely adopted in pediatric PH. Investigators have previously demonstrated that children with PH have less skeletal muscle mass in association with worse exercise performance. Interventions to increase physical activity and skeletal muscle mass may improve exercise performance and quality of life in children with PH. This study will use wearable activity monitoring devices to promote physical activity in a 16-week pilot intervention in children and teenager with PH.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 8-18 years

PH World Health Organization (WHO) diagnostic groups 1, 2, 3, or 4 (pulmonary arterial hypertension, PH due to left heart disease, PH due to lung disease, chronic thromboembolic PH)

WHO functional class I or II

Ambulatory status

Disqualifiers

WHO functional class III or IV

Single ventricle physiology

Moderate to severe renal disease (>stage 3)

Severe hepatic impairment [aspartate aminotransferase (AST)/alanine transaminase (ALT) > 2x upper limit of normal]

Trial design

Design model

Single group

Treatments tested in this trial

  • Exercise intervention

    Behavioral

    16-week home exercise intervention, enriched by mobile health technology

Treatment groups

25 Participants
are divided into 1 treatment group
Group A: Home exercise interventionOther 1 intervention

Trial outcomes

Primary outcomes

1

Change in moderate to vigorous physical activity (MVPA)

Change in MVPA (min/day) will be measured by smartwatch accelerometer from baseline over the course of the intervention

Time frame
Pre-exercise intervention and Post intervention (within 2 weeks of completion of the 16-week exercise intervention)

Secondary outcomes

1

Change in leg lean mass Z-score (LLMZ)

LLMZ will be measured by densitometry. LLMZ is a percentile score with scores -2 to 2 considered typical

Time frame
Pre-exercise intervention and Post intervention (within 2 weeks of completion of the 16-week exercise intervention)
2

Change in muscle strength

Upper extremity strength will be measured by handgrip dynamometer. Lower extremity strength will be measured by Biodex across the knee and ankle

Time frame
Pre-exercise intervention and Post intervention (within 2 weeks of completion of the 16-week exercise intervention)
3

Change in quality of life score

Score measured by completion of PedsQL questionnaire. Scores range from 0-100 with higher scores indicating better quality of life

Time frame
Pre-exercise intervention and Post intervention (within 2 weeks of completion of the 16-week exercise intervention)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Children's Hospital of Philadelphia

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator